David Berman, MD, PhD, discusses signs of dose-dependent viral control and reduction in active HIV reservoir in Phase 1/2 STRIVE trial data.
David Berman, MD, PhD
Advertisement
Executive Vice President of Research and Development at Immunocore.
Articles by David Berman, MD, PhD
Advertisement
Latest Updated Articles
Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V TrialPublished: March 17th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
A Mild Avian Influenza Season Ahead?
2
Top Infectious Disease News Stories Week of October 25-October 31
3
Qpex Biopharma’s New President Wants More Push-Pull Incentives, Opportunities for Young US Scientists
4
